AC Immune SA (ACIU) vs SAB Biotherapeutics (SABS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
SAB Biotherapeutics (SABS) has outperformed AC Immune SA (ACIU) over the past year, gaining 23.1% versus a loss of 28.4%. Over five years, ACIU leads with a -58.4% price change compared with -97.1% for SABS. SAB Biotherapeutics is the larger company by market cap ($264.3 million vs $258.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACIU | SABS |
|---|---|---|
| Share price | $2.60 | $2.91 |
| Market cap | $258.01M | $264.32M |
| 1-day change | +0.97% | +0.87% |
| YTD return | -18.15% | -22.99% |
| 1-year return | -28.41% | +23.08% |
| 5-year return | -58.41% | -97.15% |
| Forward P/E | 4.36 | — |
| EPS (TTM) | $-0.54 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.00 | $5.15 |
| 52-week low | $2.10 | $2.10 |
| Distance from 52-week high | -35.12% | -43.59% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +228.32% | +300.69% |
| Average volume | 202.76K | 489.83K |
| Shares outstanding | 99.43M | 90.99M |
| Employees | 90 | 86 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SABS has outperformed ACIU by 51.5 percentage points over the past year.
About AC Immune SA
ACIU stock →AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 90 employees
About SAB Biotherapeutics
SABS stock →SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 86 employees
ACIU vs SABS FAQ
Which is bigger, AC Immune SA or SAB Biotherapeutics?
SAB Biotherapeutics (SABS) is larger, with a market capitalization of $264.32M compared with $258.01M for AC Immune SA (ACIU).
Which stock has performed better over the past year, ACIU or SABS?
SABS returned +23.08% over the past 12 months, compared with -28.41% for ACIU (price return, excluding dividends). Past performance does not predict future results.
Are AC Immune SA and SAB Biotherapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for AC Immune SA and Biotechnology: Biological Products (No Diagnostic Substances) for SAB Biotherapeutics.